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Survival analysis of spinal muscular atrophy type I
 
Purpose: The life expectancy of patients with spinal muscular atrophy 
(SMA) type I is generally considered to be less than 2 years. Recently, 
with the introduction of proactive treatments, a longer survival and an 
improved survival rate have been reported. In this study, we analyzed 
the natural courses and survival statistics of SMA type I patients and 
compared the clinical characteristics of the patients based on their 
survival periods.
Methods: We reviewed the medical records of 14 pediatric patients 
diagnosed with SMA type I during a 9-year period. We examined the 
demographic and clinical characteristics of these patients, calculated 
their survival probabilities, and plotted survival curves as on the 
censoring date, January 1, 2010. We also compared the characteristics 
of the patients who died before the age of 24 months (early-death, ED 
group) and those who survived for 24 months or longer (long-survival, 
LS group).
Results: The mean survival time was 22.8±2.0 months. The survival 
probabilities at 6 months, 12 months, 18 months, 24 months, and 30 
months were 92.9%, 92.9%, 76.0%, 76.0%, and 65.1%, respectively. 
Birth weight was the only factor that showed a statistically significant 
difference between the ED and LS groups (P=0.048).
Conclusion: In this study, the survival probabilities at 2 years were far 
greater than expected. Because of the limited number of patients and 
information in this study, the contribution of improved supportive care 
on longer survival could not be clarified; this may be elucidated in 
larger cohort studies.
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5q131, 2). The incidence is 1 in 6,000-10,000 neonates3, 4). Because 
of the high mortality of the most serious type, the SMA type I, the 
prevalence, reported to be approximately 1 in 53,000 individuals, is 
substantially lower than that incidence5, 6).
Based on the diagnostic standards of SMA according to the 
European Neuromuscular Center (ENMC)7), the SMA type I 
Introduction 
Spinal muscular atrophy (SMA) is one of the most prevalent 
and serious single gene disorders in children. It is an autosomal 
recessive disorder caused by homozygous deletion of exon 7 of the 
survival motor neuron1 (SMN1) gene located in chromosome 
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(Werdnig-Hoffmann’s disease) patients show overall muscular 
weakness and hypotonia within 6 months after birth, and could 
never sit by themselves. According to the previous diagnostic 
standards of the SMA type I8), the age at the time of death was 
described to be less than 2 years. But according to the standards 
modified in 19997), ‘the lifespan of most patients is expected 
to be less than 2 years’. And in fact it has been reported that 
approximately 10% of patients developed SMA type I before 6 
months of age survived even longer than 5 years9). Most SMA 
type I patients die because of the rapid progress of weakening of 
muscles and respiratory failure. But recently patients are treated 
with improved supportive care such as mechanical respiratory aids 
and sufficient nutrients supply by gastrostomy, etc., which may have 
beneficial influences on the survival.
Nevertheless, studies on the survival of SMA patients are not 
sufficient and have not yet been reported in Korea. This study 
aims to analyze the clinical features of the SMA type I patients 
with special emphases on survival statistics and to compare the 
characteristics of the patients who died before 24 months and those 
who survived up to 24 months or longer.
Materials and methods
1. Subjects
The medical records of the 14 pediatric patients satisfying the 
diagnostic standards for SMA type I during the 9-year period 
between April 2000 and April 2009 at the Severance Hospital and 
Gangnam Severance Hospital, Yonsei University Medical College, 
were reviewed. According to the diagnostic criteria of Zerre and 59th 
European Neuromuscular Center (ENMC) revised in 1999, SMA 
type I patients were defined as children who showed overall muscle 
weakness, hypotonia or delayed development at birth or within 6 
months after birth, and who did not obtain the ability to sit down 
alone during the survival period. The diagnosis was confirmed 
by genetic analyses showing homozygous deletion of the survival 
motor neuron gene or by muscle biopsies.
2. Diagnostic method
SMN gene (5q12.2-q13.3) was evaluated using PCR-RFLP 
method. In patients who showed negative finding for exon 7 and 8 
deletions, they were diagnosed with SMA type I if muscle biopsy 
finding showed groups of giant type I fibers mixed with fascicles 
of severely atrophic fibers of both histochemical types that meets 
diagnostic criteria of SMA type I10). 
3. Statistical method
Kaplan-Meier method was used to calculate survival probabilities 
and plot survival curves. These analyses were conducted using death 
as an outcome. For patients who did not experience the respective 
event (death), age as of the censoring date (January 1, 2010) was 
used. 
We compared demographic and clinical characteristics of the 
patients who died before 24 months and those who survived up 
to 24 months or longer using Mann-Whitney test for continuous 
variables and Fisher exact test for categorical variables. A two-sided 
0.05 level of significance was used in all analyses.
Results
Among 14 patients who met inclusion criteria, 8 patients (57.1%) 
were male; the median gestational period was 39+0 weeks (range 
33+1-40+5); the median birth weight was 3.2 kg (range 1.4-3.9); and 
head control was possible in 4 patients (28.6%). The median age of 
symptom onset was 3.0 months (range 1.0-6.0), and the median 
age at diagnosis was 4.0 months (range 1.0-8.0). Respiratory 
support including both invasive and noninvasive ventilation was 
given in 8 patients (57.1%). In addition, artificial feeding including 
L-tube feeding and gastrostomy feeding was employed in 8 patients 
(57.1%) (Table 1). 
Genetic testing was performed in 13 patients (92.9%), of whom 
three were found to be negative for SMN1 gene deletion and 
subsequently diagnosed by muscle biopsy. Muscle biopsies were 
performed in 4 patients. The biopsy findings were round atrophic 
muscle fibers, diffuse atrophy with small round atrophic fiber and 
perimyseal fibrosis, which were compatible with SMA. In addition, 
two patients showed the deletion of NAIP gene. EMG was 
performed on 8 patients, of whom four showed the typical findings 
Table 1. Demographic and Clinical Characteristics of Patients with 
Spinal Muscular Atrophy Type I
Characteristics Data
Male, %
Gestation period, median (range), wk+day‡
Birth weight, median (range), kg‡
Head control, %
Age at symptom onset, median (range), mo
Age at diagnosis, median (range), mo
Genetic testing, %
Muscle biopsy, %
Respiratory support, %*
Artificial feeding, %†
57.1 (8/14)
39+0 (33+1-40+5)
3.2 (1.4-3.9)
28.6 (4/14)
3.0 (1.0-6.0)
4.0 (1.0-8.0)
92.9 (13/14)
28.6 (4/14)
57.1 (8/14)
57.1 (8/14)
*includes noninvasive and invasive ventilation.
†includes gastrostomy and gastric tube feeding.
‡unknown in one patient
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of SMA such as slow conduction velocity of motor neuron and mild 
to moderate denervation potential, whereas the other four showed 
non-specific findings.
Following the survival analysis, mean survival time was 22.8±2.0 
months (Fig. 1). Survival probabilities were 92.9% at 6 months, 
92.9% at 12 months, 76.0% at 18 months, 76.0% at 24 months 
and 65.1% at 30 months (Table 2). 
The demographic and clinical characteristics of the 10 patients 
(except 4 patients who were alive but did not survive more than 24 
months at the censoring date) according to survival duration are 
summarized and analyzed (Table 3, 4). Three patients died before 
24 months of age (ED) and 7 patients survived 24 months or longer 
(LS, 1 patient died at 26 months of age and 6 patients survived (age 
range: 27-79 months) until the censoring date, January 1, 2010). 
Four patients that survived as of the censoring date but less than 24 
months did not fall into either category and were not included in 
the analysis. Among the 3 patients of ED group, 2 patients weighed 
less than 2.5 kg at birth and were small for gestational age. The 
other 1 patient weighed 2.8 kg. For the LS group, birth weights 
ranged from 2.8 to 4.0 kg in 6 patients and unknown in 1 patient. 
Respiratory support was employed in 2 out of 3 patients (66.7%) of 
ED group and 5 out of 7 patients (71.4%) of LS group. In LS group, 
all 5 patients that were on ventilator underwent tracheostomy. 
In ED group, tracheostomy was done in 1 patient, and the other 
patient was on non-invasive positive pressure ventilation (NIPPV). 
Artificial feeding was done in 66.7% of ED group and 71.4% of 
LS group. Among all factors, birth weight was the only factor that 
showed a statistically significant difference between the two groups 
(P=0.048).
Discussion 
SMA type I is a common, fatal, autosomal recessive disorder of 
childhood with an estimated incidence of 1/10,000 births and a 
carrier frequency of 1/50 individuals11). Major advances have been 
made in the past 10 years in our understanding of SMA, with 
identification of the SMN gene, development of animal models, 
and improved understanding of the SMN protein function12). 
Furthermore, due to intensive supportive care as mechanical 
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Fig. 1. Kaplan-Meier survival plot of patients with spinal muscular 
atrophy Type I.
Table 2. Survival Probabilities (%)* at Different Ages (in Months) of 
Patients with Spinal Muscular Atrophy Type I
6 mo 12 mo 18 mo 24 mo 30 mo
Survival probabilities, % 92.9 92.9 76.0 76.0 65.1
* Kaplan-Meier method
Table 3. Detailed Characteristics of 10 Patients Each of the Early-Death (ED) and Long-Survival (LS) Groups
Sex
Suvival
Status
Age
(month)
Gestation 
period
(week+day)
Birth
weight 
(kg)
Age of
onset 
(month)
Age of
diagnosis
(month)
Head
control
Respiratory
support
Artificial
feeding
Genetic
testing
Biopsy EMG
ED
LS
1
2
3
1
2
3
4
5
6
7
F
M
F
M
F
M
M
F
M
M
dead
dead
dead
alive
alive
alive
alive
alive
alive
dead
16
  4
17
27
42
52
59
36
79
26
38
35
38
40
39
38
38
40+5
unknown
40
2.1
1.4
2.8
3.5
3.4
2.9
3.2
3.9
unknown
2.8
4
1
5
6
3
3
1
5
3
3
4
2
6
6
3
3
4
6
5
4
no
no
no
yes
no
no
yes
no
no
no
yes
yes
no
no
yes
yes
yes
yes
no
yes
yes
yes
no
no
yes
yes
yes
yes
no
yes
(+)
(-)
(+)
(+)
(+)
(+)
(+)
(+)
(+)
unknown
c/w* SMA
c/w* SMA
non specific
c/w*  SMA
non specific
c/w* SMA
c/w* SMA
*compatible with
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ventilation and artificial feedings, the survival of patients with 
SMA type I has significantly increased in recent years12). Therefore, 
understanding the natural history and estimating survival 
probabilities of SMA type I patients is important not only for 
providing information on prognoses to parents but also for the 
comparison of the results of future studies that evaluate the degree 
of contribution of new therapeutic modalities to improvement of 
survival. 
According to the studies reported until the early 1990s, the mean 
age at death of SMA type I patients was from 8.8 to 10 months, 
but some patients were reported to have lived up to 10 years old13-
15). From the early 1990s, for SMA type I patients, noninvasive 
pulmonary support and gastrostomy tube feeding has been applied 
more widely12). In a German study reported in 1995, the survival 
probability at the age of 2 years was 32%, 4 years was 18%, and 
10 years was 8%16). Nonetheless, reviewing the results of studies 
reported after the 2000s, the mean age at death was shown to be 
increased from 10.4 months to 4 years17, 18), and it has been reported 
that some patients lived up to 24 years old9). In a Hong Kong study 
reported in 2004, the survival probability at the age of 2 years was 
40%, 4 years was 30%, and 10 years was 30%5). In addition, in a 
study conducted on 143 SMA type I patients reported in 2007, the 
survival was reported to be increased in patients born in 1995 and 
afterward in comparison with patients prior to 199512). In our study, 
the survival probability at the age of 24 months was 76.0%, which 
is much higher than those of previous reports described above – i.e., 
32%16) and 40%5). Mean survival time calculated by Kaplan-Meier 
method was 22.8±2.0 months, but there may be some difficulty 
generalizing this data because of the statistical limitation arising 
from too few observed deaths at the time of censoring; that is, only 
4 patients experienced the event (death). 
In general, improvement of survival is thought to be mostly 
due to the changes in the supportive management for SMA 
patients5, 12, 19). In the result of a study reported in 2007, ventilatory 
support more than 16 hours daily, uses of mechanical insufflation-
exsufflation equipment, and the supply of nutrition through 
gastrostomy were shown to independently exert effects on 
survival12). Nevertheless, in a study conducted on 34 SMA type I 
patients in Netherland reported in 2008, the median age at death 
was 176 days and in regard to survival, distinct improvement was 
not shown, which was considered as the reflection of the difference 
of the attitude on medical treatments for SMA type I patients1). In 
our study, birth weight was the only factor that showed a statistically 
significant difference between the patients who died before 24 
months and those who survived 24 months or longer. Due to the 
limitation of this study, we may not be able to state that a lower 
birth weight is associated with poor prognosis such as earlier deaths. 
However, a special attention may be given to the fact that two of the 
three infants of ED group were small for gestational age, whereas 
none of the LS group was. Implementation of respiratory support 
and artificial feeding was not significantly different between the 
two groups. This may be due to a small number of patients in the 
analysis. In addition, our study has methodological limitations 
because we could not compare the patient group with the control 
group who refused treatment or who were treated prior to the 
development of proactive treatment. Another point to consider is 
that whether implementation of supportive care was a prophylactic 
measure or a rescue. Since our study is a retrospective analysis, it is 
impossible to differentiate between the two. 
In SMA type I paients, the known prognostic factor is the 
number of SMN 2 copies, and it has been shown that the more of 
SMN2 copies, the milder is the disease20-22). In addition, it has been 
reported that the disease severity of SMA could be predicted by 
the combination of the number of SMN2 copies and the deletion 
Table 4. Demographic and Clinical Characteristics of Patients with Sspinal Muscular Atrophy Type I according to Duration of Survival
<24 mo  (n=3) ≥24 mo (n=7) P-value
Male, %* 
Gestation period, median (range), wk+day*§
Birth weight, median (range), kg*§
Birth weight ≥2,500g, n                                          
Birth weight <2,500g, n
Head control, %*
Age at symptom onset, median (range), mo†
Age at diagnosis, median (range), mo*
Respiratory support, %*†
Artificial feeding, %*‡
33.3 (1/3)
38+0 (35+0-38+0)
2.1 (1.4-2.8)
1
2
0 (0/3)
4.0 (1.0-5.0)
4.0  (2.0-6.0)
66.7 (1/3)
66.7 (1/3)
71.4 (5/7)
39+3.5 (38+0-49+5)
3.3 (2.8-4.0)
6
0
28.6 (2/7)
3.0 (1.0-6.0)
4 .0 (3.0-6.0)
71.4 (5/7)
71.4 (5/7)
0.500
0.095
0.048
0.417
1.000
0.833
0.500
1.000
*P<0.05 for the comparison <24 mo vs ≥24 mo
†includes noninvasive and invasive ventilation
‡includes gastrostomy and gastric tube feeding
§unknown in one patient
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of NAIP23). SMN1 and SMN2 show 99% homology with the 
difference of only 5 nucleotides24). SMN1 produces full length 
SMN transcripts and stable SMN proteins, on the other hand, 
SMN2 produces the transcript lacking the exon 7 and truncated 
unstable SMN proteins25, 26). Nevertheless, approximately 10% 
SMN2 copies produce full length transcripts, and thus the increase 
of the number of SMN2 copies is beneficial to SMA patients, and 
thus exerts effects on the severity of SMA22, 27). In our study, the 
number of SMN2 copies in the patients was not examined, so the 
association of the number of SMN2 copies with survival could 
not be assessed. In addition, in our study, 3 patients did not show 
the homozygous deletion of SMN1 in genetic tests but diagnosed 
by muscle biopsy. Based on the result of a previous large study 
conducted on 525 typical SMA patients that the homozygous 
absence of SMN1 was identified in 92%, point mutations in 3.4%, 
and no mutation in 4.6%1), it is possible that the patients had a 
point mutation although rare or developed a disease in a different 
gene that is not linked to chromosome 5q13. In point mutation 
cases, at least one SMN1 is deleted in one chromosome, and thus 
to detect the presence of point mutation, a quantitative test that can 
determine the number of SMN1 copies may be of help1, 22). In our 
study, 2 patients out of 14 showed NAIP deletion, however we can 
not make sure if there is certain relationship with disease severity 
and this result was maybe due to limited number of patients. 
Until now, a curative treatment for SMA is not known. It is a 
disease that only palliative treatments could be given. Our study has 
limitations that only a small number of patients were involved in the 
retrospective analyses, and that only death and survival probabilities 
were considered without detailed analysis on the quality of life 
of patients such as continuous ventilation and muscle strength. 
However, such studies on the survival are helpful to provide basic 
information for future evaluation of new treatments. 
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